ReviewLupus science & medicine2018
Lupus community panel proposals for optimising clinical trials: 2018.
Review in Lupus science & medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.Rheumatology (Oxford, England) · 2022Trial
- Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial.Lupus science & medicine · 2022Trial
- Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.Rheumatology (Oxford, England) · 2021Trial
- Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.Advances in therapy · 2025Article
- Patient-Reported Factors Influencing Clinical Trial Participation: An In-depth Analysis of Patients With Lupus and Rheumatoid Arthritis.ACR open rheumatology · 2025Review
- Identifying distinct phenotypes of patients with juvenile systemic lupus erythematosus: results from a cluster analysis by the Egyptian college of rheumatology (ECR) study group.BMC pediatrics · 2024Article
- Expert consensus achieved on a working core outcome set for cutaneous lupus erythematosus research in survey following the 5th International Conference on Cutaneous Lupus Erythematosus (ICCLE).Lupus science & medicine · 2024Article
- Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).Journal of clinical trials · 2024Article
- Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.Nature reviews. Rheumatology · 2023Review
- Article
- Improving resource utilisation in SLE drug development through innovative trial design.Lupus science & medicine · 2023Review
- Recent advances in immunotherapies for lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Review
- EMBRACE: One Small Story in Lupus-One Giant Challenge in Clinical Trials.ACR open rheumatology · 2022Article
- "There's so much to be done": a qualitative study to elucidate research priorities in childhood-onset systemic lupus erythematosus.Lupus science & medicine · 2022Article
- Clinical subgroup clustering analysis in a systemic lupus erythematosus cohort from Western Pennsylvania.European journal of rheumatology · 2022Article
- Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.International journal of women's dermatology · 2021Review
- Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need.Lupus science & medicine · 2021Review
- Baricitinib: From Rheumatoid Arthritis to COVID-19.Journal of clinical pharmacology · 2021Review
- TACI haploinsufficiency protects against BAFF-driven humoral autoimmunity in mice.European journal of immunology · 2021Article
- B Cells in Systemic Lupus Erythematosus: From Disease Mechanisms to Targeted Therapies.Rheumatic diseases clinics of North America · 2021Review
Corrections and comments
- Erratum issuedCorrection:2018
Authors and funding
17 authors.
Funding
Abstract
Formidable impediments stand in the way of treatment development for lupus. These include the unwieldy size of current trials, international competition for scarce patients, complex outcome measures and a poor understanding of these outcomes in the world at large. The heterogeneity of the disease itself coupled to superimposition of variegated background polypharmacy has created enough immunological noise to virtually ensure the failure of lupus treatment trials, leaving an understandable suspicion that at least some of the results in testing failed drugs over the years may not have been negative, but merely uninterpretable. The authors have consulted with many clinical trial investigators, biopharmaceutical developers and stakeholders from government and voluntary sectors. This paper examines the available evidence that supports workable trial designs and proposes approaches to improve the odds of completing interpretable treatment development programs for lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.